Last reviewed · How we verify
A Multicenter, Randomized, Open Label, Add-on Study to Assess Efficacy and Safety of Xiyanping Injection in Subjects With Pediatric Bronchitis
This is a multicenter, randomized, open Label,add-on study.
Details
| Lead sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 240 |
| Start date | 2016-08 |
| Completion | 2020-08 |
Conditions
- Bronchitis
Interventions
- Standard treatment only
- Standard treatment+Xiyanping injection
Primary outcomes
- time to total score of the clinical symptoms/signs decreased more than 70% from baseline — up to 30 days after the last Administration
Countries
China